Cantargia Publishes Half-Year Report 2025

About this update from Cantargia Ab

[{"type":"text","content":"LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025.","length":161,"tagName":"p"},{"type":"text","content":""I started my tenure as interim CEO with a strong focus on looking to deliver at least one transformative transaction during 2025. I am delighted for all Cantargia's stakeholders, including our loyal shareholders, our employees and patients in need, that we have been able to deliver on this goal with the Otsuka agreement. Not only does the deal bring significant non-dilutive financial resources but, equally importantly, it provides clear validation of Cantargia's technology and platform. Cantargia is now on a solid footing and our next important task is to prioritize those programs and activities on which we will focus our resources going forward." said Damian Marron, Interim CEO of Cantargia.","length":720,"tagName":"p"},{"type":"text","content":"Significant events in the second quarter","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cantargia appointed Morten Lind Jensen as Chief Medical Officer.","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Treatment resistant atopic dermatitis (AD) was selected as second indication for CAN10's phase 2 program.","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Pharmacokinetic modelling confirmed the choice of Q4W dosing in phase 2 for CAN10.","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"US FDA awarded nadunolimab Fast Track Designation.","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"Cantargia signed a loan facility of SEK 50 million.","length":51,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":356,"olType":false},{"type":"text","content":"Significant events after the end of the period","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Otsuka Pharmaceuticals acquired CAN10 for an upfront of MUSD 33 plus an additional MUSD 580 in potential milestone payments and up to double digit earn-outs on future sales. The deal is expected to close in Q3 2025.","length":215,"tagName":"p"}]},{"val":[{"type":"text","content":"Preliminary results from the TRIFOUR phase 2 study in TNBC did not demonstrate a difference in ov...

More updates from Cantargia Ab